Oxurion expands its clinical research offering targeting GLP-1 and peptides

Oxurion NV, a biopharmaceutical company based in Leuven, has announced an expansion of its clinical research services, specifically targeting GLP-1 therapies, peptide treatments, and biosimilars. This initiative, led by its subsidiary Axiodis, includes services in biometrics, clinical data management, and biostatistics.

With patents for key molecules expiring, the development of biosimilars and peptide therapies is accelerating. The growing GLP-1 market is estimated to reach $150 billion by 2029. Oxurion, through its European platform, will capitalize on this momentum through acquisitions and organic growth.

Oxurion develops the operational and analytical expertise necessary to meet the growing demand for specialized clinical research. With its acquisition of Axiodis in 2025, the company aims to strengthen its position in the European market by integrating more clinical expertise and services.